VACC Vaccitech plc ADRs

Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$11.44  -0.01 (-0.09%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  01/27/2020
Outstanding shares:  34,852,426
Average volume:  16,761
Market cap:   $399,060,278
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    91864C107
ISIN:        NO0010714785
Sedol:      BL1GQG1
Valuation   (See tab for details)
PE ratio:   -11.36
PB ratio:   1.62
PS ratio:   641.31
Return on equity:   -19.10%
Net income %:   -7,425.72%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy